ICON6 phase III trial shows cediranib improves survival in recurrent ovarian cancer

Bookmark and Share
Published: 30 Sep 2013
Views: 5021
Rating:
Save
Prof Jonathan Ledermann - UCL Cancer Institute, University College London, UK

Prof Jonathan Ledermann talks to ecancer at ECC 2013 about the ICON6 trial at the 2013 European Cancer Conference in Amsterdam with ecancer.

The trial found that in women with recurrent ovarian cancer after chemotherapy responded  well to a biological therapy called cediranib.

Cediranib, which is taken in pill form, is an inhibitor of a cell signalling process involved in the formation of tumour blood vessels, essential for tumour growth, and it is the first oral inhibitor of its kind to show an improvement in the time before patients’ disease progresses and in overall survival.

The drug is a tyrosine kinase inhibitor, a type of biological therapy that blocks vascular endothelial growth factor (VEGF) receptors, which control the development of blood vessels required for growing tumours.

Read more on ecancerNews

 

ecancer's filming at ECC has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

 

 

  • Categories: